share_log

RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $32

Moomoo 24/7 ·  Apr 22 11:48

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $28 to $32.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment